National CineMedia (NASDAQ:NCMI – Get Free Report)‘s stock had its “neutral” rating restated by stock analysts at Wedbush in a research note issued to investors on Monday, RTT News reports. They presently have a $7.50 target price on the business services provider’s stock, up from their previous target price of $6.00. Wedbush’s target price points to a potential upside of 5.34% from the stock’s previous close.
Other research analysts also recently issued research reports about the stock. B. Riley boosted their price objective on shares of National CineMedia from $7.50 to $8.50 and gave the stock a “buy” rating in a report on Friday, August 16th. Barrington Research upgraded shares of National CineMedia from a “market perform” rating to an “outperform” rating and set a $7.50 price target on the stock in a research report on Tuesday, August 6th. Finally, Benchmark reaffirmed a “buy” rating and issued a $8.00 target price on shares of National CineMedia in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.88.
Get Our Latest Research Report on NCMI
National CineMedia Stock Down 0.7 %
National CineMedia (NASDAQ:NCMI – Get Free Report) last announced its earnings results on Monday, August 5th. The business services provider reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $54.70 million during the quarter, compared to the consensus estimate of $49.87 million. National CineMedia had a return on equity of 3.50% and a net margin of 78.04%. During the same quarter last year, the business earned ($0.07) EPS. Equities analysts expect that National CineMedia will post -0.05 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Eagle Investment Management LLC lifted its holdings in National CineMedia by 37.6% during the first quarter. First Eagle Investment Management LLC now owns 1,966,355 shares of the business services provider’s stock worth $10,127,000 after acquiring an additional 537,822 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in National CineMedia by 270.0% during the second quarter. Harbor Capital Advisors Inc. now owns 208,649 shares of the business services provider’s stock worth $916,000 after acquiring an additional 152,251 shares in the last quarter. Rhumbline Advisers bought a new position in National CineMedia during the second quarter worth about $427,000. Bank of New York Mellon Corp bought a new position in National CineMedia during the second quarter worth about $979,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in National CineMedia by 38.9% during the first quarter. Oppenheimer Asset Management Inc. now owns 23,897 shares of the business services provider’s stock worth $123,000 after acquiring an additional 6,690 shares in the last quarter. 69.49% of the stock is currently owned by institutional investors.
About National CineMedia
National CineMedia, Inc, through its subsidiary, National CineMedia, LLC, operates cinema advertising network in North America. It engages in the sale of advertising to national, regional, and local businesses in Noovie, a cinema advertising and entertainment show seen on movie screens; and sells advertising on its Lobby Entertainment Network, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theatre lobbies.
Further Reading
- Five stocks we like better than National CineMedia
- Overbought Stocks Explained: Should You Trade Them?
- Intel: Is Now the Time to Be Brave?Â
- Investing in the High PE Growth Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for National CineMedia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National CineMedia and related companies with MarketBeat.com's FREE daily email newsletter.